Presentation is loading. Please wait.

Presentation is loading. Please wait.

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience  Lynette M. Sholl, MD, Dara.

Published byΠελαγία Βασιλόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience  Lynette M. Sholl, MD, Dara."— Presentation transcript:

1 Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience  Lynette M. Sholl, MD, Dara L. Aisner, MD, PhD, Marileila Varella-Garcia, PhD, Lynne D. Berry, PhD, Dora Dias-Santagata, PhD, Ignacio I. Wistuba, MD, Heidi Chen, PhD, Junya Fujimoto, MD, PhD, Kelly Kugler, BA, Wilbur A. Franklin, MD, A. John Iafrate, MD, PhD, Marc Ladanyi, MD, Mark G. Kris, MD, Bruce E. Johnson, MD, Paul A. Bunn, MD, John D. Minna, MD, David J. Kwiatkowski, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 5, Pages (May 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Mutations identified in the LCMC cohort. A pie chart is shown in which the size of each slice is proportional to the mutation frequency in the full genotyping set of 733 patients. Cases with two mutations are represented only once based on the mutation that primarily dictated clinical care in each patient. As a result, the frequencies of ALK, MET, and PIK3CA alterations appear lower in this figure. (See Table 2 for details.) Frequencies presented here also differ slightly for some genes in comparison with frequencies for the any-genotyping group (n = 1007). See details of the full-genotyping versus any-genotyping cohorts and a comprehensive breakdown of all mutations identified in our original article on the LCMC experience, Ref. 14. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Demographic and prognostic associations with any and individual specific mutations. Statistically significant and other notable associations are shown in the form of bar graphs for several mutation types. “Any” refers to any identified mutation. KRAS, EGFR, and ERBB2 consist of all point mutations occurring in those genes; ALK refers to translocations involving ALK, and MET refers to amplification of the MET locus, identified by FISH. More detailed demographic and prognostic association data are provided in Supplemental Table 7 (Supplemental Digital Content 1, Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience  Lynette M. Sholl, MD, Dara."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 
Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas  Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas  Rong Fang, PhD, Chao Zheng, PhD, Yihua.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor  Sai F. Yeung, BSc, Joanna H.M. Tong,

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor  Sai F. Yeung, BSc, Joanna H.M. Tong,
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Similar presentations

Ads by Google